Tech Company Financing Transactions

Newleos Therapeutics Funding Round

Goldman Sachs, Arkin Bio-Ventures and DCVC Bio participated in a $93.5 million Series A funding round for Newleos Therapeutics. The round was announced on 2/13/2025.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Life Sciences

Mailing Address

800 Boylston St. 1715
Boston, MA 02199
USA

Phone

Undisclosed

Website

www.newleos.com

Email Address

[email protected]

Overview

Our mission is to provide a new dawn or "eos" for patients suffering from a variety of mental health conditions by developing next generation, first- and best-in-class therapies.? Newleos Therapeutics is a clinical stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development. Newleos' clinical-stage pipeline was in-licensed from Roche and includes multiple oral small molecules targeting novel mechanisms across a broad range of indications, including generalized anxiety, social anxiety, substance use disorders, and cognitive impairment.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

David Donabedian

        

Browse more venture capital transactions:

Prev: 2/13/2025: Abcuro venture capital transaction
Next: 2/13/2025: Soter Insure venture capital transaction

Share this article

Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary